The 2023 Report on Stem Cell Technologies and Applications: World Market Segmentation by City
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a 'borderless world', cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries. It does so by reporting the estimated market size (in terms of latent demand) for each major city of the world. It then ranks these cities and reports them in terms of their size as a percent of the country where they are located, their geographic region (e.g. Africa, Asia, Europe, Middle East, North America, Latin America), and the total world market.
In this report we define the sales of stem cell technologies and applications as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aastrom Biosciences, Advanced Cell Technology, AgeX Therapeutics, Alder Biopharmaceuticals, Alkem, AllCells, Allergan, AlloSource, Americord, Amgen, Angiocrine Bioscience, Anterogen, Apceth, Arteriocyte, Associated Press, Astellas Pharma, Asterias Biotherapeutics, Athersys, Auriga Ventures, Axiogenesis, Bank a Tooth, Baxter, BaYi Brain Hospital, BioCardia, BioE, Biogenea-Cellgenea, BIOHEART, Biologic Therapies, BioMet Orthopedics, Biosciences, Biotechnology, BioTime, Blackstone, Bloodworks, Bluebird Bio, Brain Somatic Mosaicism, Caladrius Biosciences, California Institute for Regenerative Medicine (CIRM), Calimmune, Capricor, Cardio3, Caribou, Carolinas Cord Blood Bank (CCBB), Casey Eye Institute, Cedars-Sinai Heart Institute, Celgene, Cell Cure Neurosciences, CellCentric, Cellectis, Cellerant Therapeutics, Cellerix, CELLTREE, Cellular Biomedicine Group, Center for International Blood and Marrow Transplant Research (CIBMTR), Cephalon, Cesca Therapeutics, Ceylad, China Cord Blood, Chugai Pharmaceutical Company, CJ CheilJedang, Clal Biotechnologies Industries, Cleveland BioLabs, ClinImmune Labs, Cochrane, Cognate Bioservices, Cook General, Cord Blood America, Cordvida, CRISPR Therapeutics, Cryo-Cell, CryoCord, CryoHaldco, Cryonix CJSC, Cryo-Save, CryoViva, CXR Biosciences, Cynata Therapeutics, Cytori Therapeutics, Denali Ventures, Dendreon, Dong-A Pharmaceuticals Company, Dynamics, Elbit Imaging, Eli Lilly, EpiStem, ESI BIO, EuroStemCell, Evotec, Fate Therapeutics, FDS Pharma, Fondazione Centro San Raffaele, Forbion Capital Partners, Forticell Bioscience, Forty Seven, Fresenius, FUJIFILM Company, Ltd., Future Health Biobank, Gamida Cell, Gemabank, Gene Cell International, Genetrix Group, Geron, Gilead, GlaxoSmithKline, GlobalStem, Globocan, GSK, Howard Hughes Medical Institute, HSCI, Humacyte, Human Stem Cells Institute, Immunocellular Therapeutics, Immunovative Therapies, Indian Department of Biotechnology, Innovative Cellular Therapeutics, Insception Biosciences, Intellia Therapeutics, IntelliCell Biosciences, International, IPS Academia Japan, Isar Medical Centre, Israel Healthcare venture, Japan Institute of Biomedical Research., JCR Pharmaceuticals, JingYuan Bio., Johnson & Johnson, Kirby Institute, Lifebank Cryogenics, LifeCord, LifeMap Sciences, LifeSouth Community Blood Centers, Inc., Lineage Cell Therapeutics, Lonza Group, MaxCyte, Mayo Clinic, MedCell Bioscience, Medipost, Medistem Panama, Medtronic, PLC, Mesoblast, Miltenyi Biotec, National Dental Pulp Laboratory, NeoStem, Neuralstem, Neurolastem, New England Cord Blood Bank, Nohla Therapeutics, Novartis, NovoCell, NurOwn, NuVasive, Ocata Therapeutics, Omidubicel, Oncocyte, Opexa Therapeutics, Orchard Therapeutics, OrLife Bio, Orthofix, Osiris, Pahrump Valley Times, Pfizer, Pharmicell, Pharmsynthez, Plasticell, Pluristem Therapeutics, Polyphor, Poseida Therapeutics, Precious Cell Group, Prix Galien, PsychENCODE, Pulp Laboratory, Q Therapeutics, QYuns Therapeutics, ReCyte Therapeutics, Ree Labs, Regenerative Sciences, Regenerex, Regeneron, Regeneus, Reliance Group, ReNeuron, RepliCel Life Sciences, Reprobank, Reprocell, Riken, Roche, Roslin Cellab, RTI Biologics, RUSNANO, RVC OJSC, SanBio, Sangamo Biosciences, Sanofi, Seneca Biopharma, S-Evans Biosciences, Sorrento Therapeutics, Spinesmith Partners, SSM Cardinal Glennon, St. Jude’s, Stem Cell Bank, Stemcell Technologies, StemCore, Stemcyte, Stemedica Cell Technologies, StemGen, StemImmune, Inc., Stemina Biomarker Discovery, StemSave, Store-a-tooth, SwissMedic, SynBio, Systems, Takara Bio, Takeda, TAP Biosystems, Teva, The Zon Laboratory, TiGenix, Tong Yuan Stem Cell, Tooth Bank, TrakCel, TransCell, Translational Biosciences, U.S. Stem Cell, UCL Business, UniQure, United Therapeutics, US Stem Cell, Inc., Valeant, VAULT Sc, Inc., Vericel, Vesta Therapeutics, ViaCord, ViaCyte, ViroMed, VistaGen Therapeutics, Vita34, Vitro Biopharma, W.L. Gore & Associates, WA Optimum Health Care, and WHO. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
In this report we define the sales of stem cell technologies and applications as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aastrom Biosciences, Advanced Cell Technology, AgeX Therapeutics, Alder Biopharmaceuticals, Alkem, AllCells, Allergan, AlloSource, Americord, Amgen, Angiocrine Bioscience, Anterogen, Apceth, Arteriocyte, Associated Press, Astellas Pharma, Asterias Biotherapeutics, Athersys, Auriga Ventures, Axiogenesis, Bank a Tooth, Baxter, BaYi Brain Hospital, BioCardia, BioE, Biogenea-Cellgenea, BIOHEART, Biologic Therapies, BioMet Orthopedics, Biosciences, Biotechnology, BioTime, Blackstone, Bloodworks, Bluebird Bio, Brain Somatic Mosaicism, Caladrius Biosciences, California Institute for Regenerative Medicine (CIRM), Calimmune, Capricor, Cardio3, Caribou, Carolinas Cord Blood Bank (CCBB), Casey Eye Institute, Cedars-Sinai Heart Institute, Celgene, Cell Cure Neurosciences, CellCentric, Cellectis, Cellerant Therapeutics, Cellerix, CELLTREE, Cellular Biomedicine Group, Center for International Blood and Marrow Transplant Research (CIBMTR), Cephalon, Cesca Therapeutics, Ceylad, China Cord Blood, Chugai Pharmaceutical Company, CJ CheilJedang, Clal Biotechnologies Industries, Cleveland BioLabs, ClinImmune Labs, Cochrane, Cognate Bioservices, Cook General, Cord Blood America, Cordvida, CRISPR Therapeutics, Cryo-Cell, CryoCord, CryoHaldco, Cryonix CJSC, Cryo-Save, CryoViva, CXR Biosciences, Cynata Therapeutics, Cytori Therapeutics, Denali Ventures, Dendreon, Dong-A Pharmaceuticals Company, Dynamics, Elbit Imaging, Eli Lilly, EpiStem, ESI BIO, EuroStemCell, Evotec, Fate Therapeutics, FDS Pharma, Fondazione Centro San Raffaele, Forbion Capital Partners, Forticell Bioscience, Forty Seven, Fresenius, FUJIFILM Company, Ltd., Future Health Biobank, Gamida Cell, Gemabank, Gene Cell International, Genetrix Group, Geron, Gilead, GlaxoSmithKline, GlobalStem, Globocan, GSK, Howard Hughes Medical Institute, HSCI, Humacyte, Human Stem Cells Institute, Immunocellular Therapeutics, Immunovative Therapies, Indian Department of Biotechnology, Innovative Cellular Therapeutics, Insception Biosciences, Intellia Therapeutics, IntelliCell Biosciences, International, IPS Academia Japan, Isar Medical Centre, Israel Healthcare venture, Japan Institute of Biomedical Research., JCR Pharmaceuticals, JingYuan Bio., Johnson & Johnson, Kirby Institute, Lifebank Cryogenics, LifeCord, LifeMap Sciences, LifeSouth Community Blood Centers, Inc., Lineage Cell Therapeutics, Lonza Group, MaxCyte, Mayo Clinic, MedCell Bioscience, Medipost, Medistem Panama, Medtronic, PLC, Mesoblast, Miltenyi Biotec, National Dental Pulp Laboratory, NeoStem, Neuralstem, Neurolastem, New England Cord Blood Bank, Nohla Therapeutics, Novartis, NovoCell, NurOwn, NuVasive, Ocata Therapeutics, Omidubicel, Oncocyte, Opexa Therapeutics, Orchard Therapeutics, OrLife Bio, Orthofix, Osiris, Pahrump Valley Times, Pfizer, Pharmicell, Pharmsynthez, Plasticell, Pluristem Therapeutics, Polyphor, Poseida Therapeutics, Precious Cell Group, Prix Galien, PsychENCODE, Pulp Laboratory, Q Therapeutics, QYuns Therapeutics, ReCyte Therapeutics, Ree Labs, Regenerative Sciences, Regenerex, Regeneron, Regeneus, Reliance Group, ReNeuron, RepliCel Life Sciences, Reprobank, Reprocell, Riken, Roche, Roslin Cellab, RTI Biologics, RUSNANO, RVC OJSC, SanBio, Sangamo Biosciences, Sanofi, Seneca Biopharma, S-Evans Biosciences, Sorrento Therapeutics, Spinesmith Partners, SSM Cardinal Glennon, St. Jude’s, Stem Cell Bank, Stemcell Technologies, StemCore, Stemcyte, Stemedica Cell Technologies, StemGen, StemImmune, Inc., Stemina Biomarker Discovery, StemSave, Store-a-tooth, SwissMedic, SynBio, Systems, Takara Bio, Takeda, TAP Biosystems, Teva, The Zon Laboratory, TiGenix, Tong Yuan Stem Cell, Tooth Bank, TrakCel, TransCell, Translational Biosciences, U.S. Stem Cell, UCL Business, UniQure, United Therapeutics, US Stem Cell, Inc., Valeant, VAULT Sc, Inc., Vericel, Vesta Therapeutics, ViaCord, ViaCyte, ViroMed, VistaGen Therapeutics, Vita34, Vitro Biopharma, W.L. Gore & Associates, WA Optimum Health Care, and WHO. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
1 INTRODUCTION & METHODOLOGY
1.1 OVERVIEW AND DEFINITIONS
1.2 MARKET POTENTIAL ESTIMATION METHODOLOGY
1.2.1 OVERVIEW
1.2.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.2.3 THE METHODOLOGY
1.2.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
1.2.3.2 STEP 2. FILTERING AND SMOOTHING
1.2.3.3 STEP 3. FILLING IN MISSING VALUES
1.2.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
1.2.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
1.2.3.6 STEP 6. AGGREGATION AND BENCHMARKING
1.3 FREQUENTLY ASKED QUESTIONS (FAQ)
1.3.1 CATEGORY DEFINITION
1.3.2 UNITS
1.3.3 METHODOLOGY
2 USING THE DATA
3 CITY SEGMENTS RANKED BY MARKET SIZE
3.1 TOP 15 MARKETS
3.2 MARKETS 16 TO
3.3 REMAINING CITIES BY MARKET RANK
4 CITY SEGMENTS IN ALPHABETICAL ORDER
4.1 A: FROM AALBORG TO AZUL
4.2 B: FROM BABAHOYO TO BYUMBA TOWN
4.3 C: FROM CAAGUAZU TO CZ?STOCHOWA
4.4 D: FROM DA LAT TO DZUUNMOD
4.5 E: FROM EBEBIYIN TO EUNOS GRC
4.6 F: FROM FACATATIV? TO FUZHOU
4.7 G: FROM GABES TO GYUMRI
4.8 H: FROM HA LONG (HONG GAI) TO HYESAN
4.9 I: FROM IALTA (YALTA) TO IZMIT
4.10 J: FROM JABALPUR TO JYVASKYLA
4.11 K: FROM KABANKALAN TO KYZYLORDA
4.12 L: FROM LA BANDA TO LYSYCHANS'K
4.13 M: FROM MA`ARRAT AN NU`MAN TO MZUZU
4.14 N: FROM NABEREZHNYE TCHELNY TO NZEREKORE
4.15 O: FROM OAKVILLE TO OZAMIS CITY
4.16 P: FROM PABNA TO PYONGYANG
4.17 Q: FROM QAEMSHAHR TO QUITO
4.18 R: FROM RA'ANNANA TO RZESZ?W
4.19 S: FROM SAANICH TO SZOMBATHELY
4.20 T: FROM TABACO TO TYUMEN
4.21 U: FROM UBERABA TO UZHHOROD
4.22 V: FROM VACOAS-PHOENIX TO VUNG TAU
4.23 W: FROM WA TO WUXI
4.24 X: FROM XAI-XAI TO XUZHOU
4.25 Y: FROM YAKUTSK TO YUHUA
4.26 Z: FROM ZAANSTAD TO ZWOLLE
5 CITY SEGMENTS RANKED BY COUNTRY
5.1 AFGHANISTAN
5.2 ALBANIA
5.3 ALGERIA
5.4 AMERICAN SAMOA
5.5 ANDORRA
5.6 ANGOLA
5.7 ANTIGUA AND BARBUDA
5.8 ARGENTINA
5.9 ARMENIA
5.10 ARUBA
5.11 AUSTRALIA
5.12 AUSTRIA
5.13 AZERBAIJAN
5.14 BAHRAIN
5.15 BANGLADESH
5.16 BARBADOS
5.17 BELARUS
5.18 BELGIUM
5.19 BELIZE
5.20 BENIN
5.21 BERMUDA
5.22 BHUTAN
5.23 BOLIVIA
5.24 BOSNIA AND HERZEGOVINA
5.25 BOTSWANA
5.26 BRAZIL
5.27 BRUNEI
5.28 BULGARIA
5.29 BURKINA FASO
5.30 BURUNDI
5.31 CAMBODIA
5.32 CAMEROON
5.33 CANADA
5.34 CAPE VERDE
5.35 CHAD
5.36 CHILE
5.37 CHINA
5.38 CHRISTMAS ISLAND
5.39 COLOMBIA
5.40 COMOROS
5.41 COSTA RICA
5.42 COTE D'IVOIRE
5.43 CROATIA
5.44 CUBA
5.45 CYPRUS
5.46 DENMARK
5.47 DJIBOUTI
5.48 DOMINICA
5.49 ECUADOR
5.50 EGYPT
5.51 EL SALVADOR
5.52 EQUATORIAL GUINEA
5.53 ERITREA
5.54 ESTONIA
5.55 ESWATINI
5.56 ETHIOPIA
5.57 FIJI
5.58 FINLAND
5.59 FRANCE
5.60 FRENCH POLYNESIA
5.61 GABON
5.62 GEORGIA
5.63 GERMANY
5.64 GHANA
5.65 GREECE
5.66 GREENLAND
5.67 GRENADA
5.68 GUAM
5.69 GUATEMALA
5.70 GUINEA
5.71 GUINEA-BISSAU
5.72 GUYANA
5.73 HAITI
5.74 HONDURAS
5.75 HONG KONG
5.76 HUNGARY
5.77 ICELAND
5.78 INDIA
5.79 INDONESIA
5.80 IRAN
5.81 IRAQ
5.82 IRELAND
5.83 ISRAEL
5.84 ITALY
5.85 JAMAICA
5.86 JAPAN
5.87 JORDAN
5.88 KAZAKHSTAN
5.89 KENYA
5.90 KIRIBATI
5.91 KOSOVO
5.92 KUWAIT
5.93 KYRGYZSTAN
5.94 LAOS
5.95 LATVIA
5.96 LEBANON
5.97 LESOTHO
5.98 LIBERIA
5.99 LIBYA
5.100 LIECHTENSTEIN
5.101 LITHUANIA
5.102 LUXEMBOURG
5.103 MACAU
5.104 MACEDONIA
5.105 MADAGASCAR
5.106 MALAWI
5.107 MALAYSIA
5.108 MALI
5.109 MALTA
5.110 MAURITANIA
5.111 MAURITIUS
5.112 MEXICO
5.113 MICRONESIA
5.114 MOLDOVA
5.115 MONACO
5.116 MONGOLIA
5.117 MONTENEGRO
5.118 MOROCCO
5.119 MOZAMBIQUE
5.120 MYANMAR
5.121 NAMIBIA
5.122 NAURU
5.123 NEPAL
5.124 NEW CALEDONIA
5.125 NEW ZEALAND
5.126 NICARAGUA
5.127 NIGER
5.128 NIGERIA
5.129 NIUE
5.130 NORFOLK ISLAND
5.131 NORTH KOREA
5.132 NORWAY
5.133 OMAN
5.134 PAKISTAN
5.135 PALAU
5.136 PALESTINE
5.137 PANAMA
5.138 PAPUA NEW GUINEA
5.139 PARAGUAY
5.140 PERU
5.141 POLAND
5.142 PORTUGAL
5.143 PUERTO RICO
5.144 QATAR
5.145 ROMANIA
5.146 RUSSIA
5.147 RWANDA
5.148 SAMOA
5.149 SAN MARINO
5.150 SAO TOME E PRINCIPE
5.151 SAUDI ARABIA
5.152 SENEGAL
5.153 SERBIA
5.154 SEYCHELLES
5.155 SIERRA LEONE
5.156 SINGAPORE
5.157 SLOVAKIA
5.158 SLOVENIA
5.159 SOMALIA
5.160 SOUTH AFRICA
5.161 SOUTH KOREA
5.162 SOUTH SUDAN
5.163 SPAIN
5.164 SRI LANKA
5.165 ST. KITTS AND NEVIS
5.166 ST. LUCIA
5.167 ST. VINCENT AND THE GRENADINES
5.168 SUDAN
5.169 SURINAME
5.170 SWEDEN
5.171 SWITZERLAND
5.172 SYRIA
5.173 TAIWAN
5.174 TAJIKISTAN
5.175 TANZANIA
5.176 THAILAND
5.177 THE BAHAMAS
5.178 THE BRITISH VIRGIN ISLANDS
5.179 THE CAYMAN ISLANDS
5.180 THE CENTRAL AFRICAN REPUBLIC
5.181 THE COOK ISLANDS
5.182 THE CZECH REPUBLIC
5.183 THE DEMOCRATIC REPUBLIC OF THE CONGO
5.184 THE DOMINICAN REPUBLIC
5.185 THE FALKLAND ISLANDS
5.186 THE GAMBIA
5.187 THE MALDIVES
5.188 THE MARSHALL ISLANDS
5.189 THE NETHERLANDS
5.190 THE NORTHERN MARIANA ISLANDS
5.191 THE PHILIPPINES
5.192 THE REPUBLIC OF THE CONGO
5.193 THE SOLOMON ISLANDS
5.194 THE U.S. VIRGIN ISLANDS
5.195 THE UNITED ARAB EMIRATES
5.196 THE UNITED KINGDOM
5.197 THE UNITED STATES
5.198 TIMOR-LESTE
5.199 TOGO
5.200 TONGA
5.201 TRINIDAD AND TOBAGO
5.202 TUNISIA
5.203 TURKEY
5.204 TURKMENISTAN
5.205 TUVALU
5.206 UGANDA
5.207 UKRAINE
5.208 URUGUAY
5.209 UZBEKISTAN
5.210 VANUATU
5.211 VENEZUELA
5.212 VIETNAM
5.213 WALLIS AND FUTUNA
5.214 WESTERN SAHARA
5.215 YEMEN
5.216 ZAMBIA
5.217 ZIMBABWE
6 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
6.1 DISCLAIMERS & SAFE HARBOR
6.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
1.1 OVERVIEW AND DEFINITIONS
1.2 MARKET POTENTIAL ESTIMATION METHODOLOGY
1.2.1 OVERVIEW
1.2.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.2.3 THE METHODOLOGY
1.2.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
1.2.3.2 STEP 2. FILTERING AND SMOOTHING
1.2.3.3 STEP 3. FILLING IN MISSING VALUES
1.2.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
1.2.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
1.2.3.6 STEP 6. AGGREGATION AND BENCHMARKING
1.3 FREQUENTLY ASKED QUESTIONS (FAQ)
1.3.1 CATEGORY DEFINITION
1.3.2 UNITS
1.3.3 METHODOLOGY
2 USING THE DATA
3 CITY SEGMENTS RANKED BY MARKET SIZE
3.1 TOP 15 MARKETS
3.2 MARKETS 16 TO
3.3 REMAINING CITIES BY MARKET RANK
4 CITY SEGMENTS IN ALPHABETICAL ORDER
4.1 A: FROM AALBORG TO AZUL
4.2 B: FROM BABAHOYO TO BYUMBA TOWN
4.3 C: FROM CAAGUAZU TO CZ?STOCHOWA
4.4 D: FROM DA LAT TO DZUUNMOD
4.5 E: FROM EBEBIYIN TO EUNOS GRC
4.6 F: FROM FACATATIV? TO FUZHOU
4.7 G: FROM GABES TO GYUMRI
4.8 H: FROM HA LONG (HONG GAI) TO HYESAN
4.9 I: FROM IALTA (YALTA) TO IZMIT
4.10 J: FROM JABALPUR TO JYVASKYLA
4.11 K: FROM KABANKALAN TO KYZYLORDA
4.12 L: FROM LA BANDA TO LYSYCHANS'K
4.13 M: FROM MA`ARRAT AN NU`MAN TO MZUZU
4.14 N: FROM NABEREZHNYE TCHELNY TO NZEREKORE
4.15 O: FROM OAKVILLE TO OZAMIS CITY
4.16 P: FROM PABNA TO PYONGYANG
4.17 Q: FROM QAEMSHAHR TO QUITO
4.18 R: FROM RA'ANNANA TO RZESZ?W
4.19 S: FROM SAANICH TO SZOMBATHELY
4.20 T: FROM TABACO TO TYUMEN
4.21 U: FROM UBERABA TO UZHHOROD
4.22 V: FROM VACOAS-PHOENIX TO VUNG TAU
4.23 W: FROM WA TO WUXI
4.24 X: FROM XAI-XAI TO XUZHOU
4.25 Y: FROM YAKUTSK TO YUHUA
4.26 Z: FROM ZAANSTAD TO ZWOLLE
5 CITY SEGMENTS RANKED BY COUNTRY
5.1 AFGHANISTAN
5.2 ALBANIA
5.3 ALGERIA
5.4 AMERICAN SAMOA
5.5 ANDORRA
5.6 ANGOLA
5.7 ANTIGUA AND BARBUDA
5.8 ARGENTINA
5.9 ARMENIA
5.10 ARUBA
5.11 AUSTRALIA
5.12 AUSTRIA
5.13 AZERBAIJAN
5.14 BAHRAIN
5.15 BANGLADESH
5.16 BARBADOS
5.17 BELARUS
5.18 BELGIUM
5.19 BELIZE
5.20 BENIN
5.21 BERMUDA
5.22 BHUTAN
5.23 BOLIVIA
5.24 BOSNIA AND HERZEGOVINA
5.25 BOTSWANA
5.26 BRAZIL
5.27 BRUNEI
5.28 BULGARIA
5.29 BURKINA FASO
5.30 BURUNDI
5.31 CAMBODIA
5.32 CAMEROON
5.33 CANADA
5.34 CAPE VERDE
5.35 CHAD
5.36 CHILE
5.37 CHINA
5.38 CHRISTMAS ISLAND
5.39 COLOMBIA
5.40 COMOROS
5.41 COSTA RICA
5.42 COTE D'IVOIRE
5.43 CROATIA
5.44 CUBA
5.45 CYPRUS
5.46 DENMARK
5.47 DJIBOUTI
5.48 DOMINICA
5.49 ECUADOR
5.50 EGYPT
5.51 EL SALVADOR
5.52 EQUATORIAL GUINEA
5.53 ERITREA
5.54 ESTONIA
5.55 ESWATINI
5.56 ETHIOPIA
5.57 FIJI
5.58 FINLAND
5.59 FRANCE
5.60 FRENCH POLYNESIA
5.61 GABON
5.62 GEORGIA
5.63 GERMANY
5.64 GHANA
5.65 GREECE
5.66 GREENLAND
5.67 GRENADA
5.68 GUAM
5.69 GUATEMALA
5.70 GUINEA
5.71 GUINEA-BISSAU
5.72 GUYANA
5.73 HAITI
5.74 HONDURAS
5.75 HONG KONG
5.76 HUNGARY
5.77 ICELAND
5.78 INDIA
5.79 INDONESIA
5.80 IRAN
5.81 IRAQ
5.82 IRELAND
5.83 ISRAEL
5.84 ITALY
5.85 JAMAICA
5.86 JAPAN
5.87 JORDAN
5.88 KAZAKHSTAN
5.89 KENYA
5.90 KIRIBATI
5.91 KOSOVO
5.92 KUWAIT
5.93 KYRGYZSTAN
5.94 LAOS
5.95 LATVIA
5.96 LEBANON
5.97 LESOTHO
5.98 LIBERIA
5.99 LIBYA
5.100 LIECHTENSTEIN
5.101 LITHUANIA
5.102 LUXEMBOURG
5.103 MACAU
5.104 MACEDONIA
5.105 MADAGASCAR
5.106 MALAWI
5.107 MALAYSIA
5.108 MALI
5.109 MALTA
5.110 MAURITANIA
5.111 MAURITIUS
5.112 MEXICO
5.113 MICRONESIA
5.114 MOLDOVA
5.115 MONACO
5.116 MONGOLIA
5.117 MONTENEGRO
5.118 MOROCCO
5.119 MOZAMBIQUE
5.120 MYANMAR
5.121 NAMIBIA
5.122 NAURU
5.123 NEPAL
5.124 NEW CALEDONIA
5.125 NEW ZEALAND
5.126 NICARAGUA
5.127 NIGER
5.128 NIGERIA
5.129 NIUE
5.130 NORFOLK ISLAND
5.131 NORTH KOREA
5.132 NORWAY
5.133 OMAN
5.134 PAKISTAN
5.135 PALAU
5.136 PALESTINE
5.137 PANAMA
5.138 PAPUA NEW GUINEA
5.139 PARAGUAY
5.140 PERU
5.141 POLAND
5.142 PORTUGAL
5.143 PUERTO RICO
5.144 QATAR
5.145 ROMANIA
5.146 RUSSIA
5.147 RWANDA
5.148 SAMOA
5.149 SAN MARINO
5.150 SAO TOME E PRINCIPE
5.151 SAUDI ARABIA
5.152 SENEGAL
5.153 SERBIA
5.154 SEYCHELLES
5.155 SIERRA LEONE
5.156 SINGAPORE
5.157 SLOVAKIA
5.158 SLOVENIA
5.159 SOMALIA
5.160 SOUTH AFRICA
5.161 SOUTH KOREA
5.162 SOUTH SUDAN
5.163 SPAIN
5.164 SRI LANKA
5.165 ST. KITTS AND NEVIS
5.166 ST. LUCIA
5.167 ST. VINCENT AND THE GRENADINES
5.168 SUDAN
5.169 SURINAME
5.170 SWEDEN
5.171 SWITZERLAND
5.172 SYRIA
5.173 TAIWAN
5.174 TAJIKISTAN
5.175 TANZANIA
5.176 THAILAND
5.177 THE BAHAMAS
5.178 THE BRITISH VIRGIN ISLANDS
5.179 THE CAYMAN ISLANDS
5.180 THE CENTRAL AFRICAN REPUBLIC
5.181 THE COOK ISLANDS
5.182 THE CZECH REPUBLIC
5.183 THE DEMOCRATIC REPUBLIC OF THE CONGO
5.184 THE DOMINICAN REPUBLIC
5.185 THE FALKLAND ISLANDS
5.186 THE GAMBIA
5.187 THE MALDIVES
5.188 THE MARSHALL ISLANDS
5.189 THE NETHERLANDS
5.190 THE NORTHERN MARIANA ISLANDS
5.191 THE PHILIPPINES
5.192 THE REPUBLIC OF THE CONGO
5.193 THE SOLOMON ISLANDS
5.194 THE U.S. VIRGIN ISLANDS
5.195 THE UNITED ARAB EMIRATES
5.196 THE UNITED KINGDOM
5.197 THE UNITED STATES
5.198 TIMOR-LESTE
5.199 TOGO
5.200 TONGA
5.201 TRINIDAD AND TOBAGO
5.202 TUNISIA
5.203 TURKEY
5.204 TURKMENISTAN
5.205 TUVALU
5.206 UGANDA
5.207 UKRAINE
5.208 URUGUAY
5.209 UZBEKISTAN
5.210 VANUATU
5.211 VENEZUELA
5.212 VIETNAM
5.213 WALLIS AND FUTUNA
5.214 WESTERN SAHARA
5.215 YEMEN
5.216 ZAMBIA
5.217 ZIMBABWE
6 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
6.1 DISCLAIMERS & SAFE HARBOR
6.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
